Skip to main content
. 2013 Nov 19;36(1):172–181. doi: 10.1007/s11096-013-9876-7

Fig. 3.

Fig. 3

Proportion of imatinib users achieving treatment responses at various points up to the 18th month of treatment. ChR complete hematologic response, PCyR partial cytogenetic response, CCyR complete cytogenetic response, MMR major molecular response, CMR complete molecular response